IF YOU’D SURVIVED melanoma – the deadliest form of skin cancer – you’d avoid the sun like the plague, right? Unfortunately, that’s not always the case. When it comes to patients who’ve gone through melanoma treatment, recent findings on prevention are mixed. Just as a new study reinforces that regular self-checks remain the first line […]
The Latest on Skin Cancer: Avoiding Melanoma Read More »
For Andrew Forrest and his wife, Nicola – as for so many people – the fight against cancer is personal. Both sides of their family have been afflicted, dating all the way back to Mr Forrest’s great-great-uncle John – the first premier of Western Australia – who was killed by melanoma 99 years ago. More
Andrew Forrest draws on Family experience in push to Eliminate Cancer Read More »
Ronald DePinho, M.D., professor of biology and former president, The University of Texas MD Anderson Cancer Center, is among the recipients of the 2017 Ellis Island Medal of Honor from the National Ethnic Coalition of Organizations (NECO). The medal recognizes those who have made it their mission to share their wealth of knowledge, indomitable courage,
Ellis Island Medal of Honor Presented to Ronald DePinho, M.D. Read More »
A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC). Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-associated protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset
Effective Combinatorial Immunotherapy for Castration-Resistant Prostate Cancer Read More »
We used an inducible KrasG12D-driven PDAC mouse model to establish that advanced PDAC remains strictly dependent on KrasG12D expression. This work provides in vivo mechanistic insights into how oncogenic Kras promotes metabolic reprogramming in native tumors and illuminates potential metabolic targets that can be exploited for therapeutic benefit. Read the Abstract Download the PDF
Established the principle of “synthetic essentiality” and identified CHD1 as a synthetic-essential gene in PTEN-deficient cancers. This study identified a novel PTEN pathway in cancer and provided a framework for the discovery of ‘trackable’ targets in cancers that harbor specific tumor-suppressor deficiencies. Read the Abstract Download the PDF
Synthetic Essentiality of Chromatin Remodelling Factor CHD1 in PTEN-deficient Cancer Read More »
To understand the role of oncogenic KRAS in CRC, we engineered a mouse model of metastatic CRC that harbors an inducible oncogenic Kras allele (Krasmut ) and conditional null alleles of Apc and Trp53 (iKAP). The iKAP model recapitulates human tumor progression from adenoma through metastases. Read the Abstract Download the PDF
Oncogenic Kras drives Invasion and maintains Metastases in Colorectal Cancer Read More »
To the Editor: Re “Minorities Face Extra Hurdles in Cancer Trials” (“Cell Wars” series, front page, Dec. 24): Here at MD Anderson Cancer Center, where about half of all patients participate in clinical trials, minority inclusion is a priority. And data from our diverse catchment area show that minority patients, in fact, have the highest
Joining Clinical Trials Read More »
Homozygous deletion of SMAD4 often results in loss of the neighboring metabolic gene malic enzyme 2 (ME2), creating a cancer-specific metabolic vulnerability upon targeting of its paralogous isoform ME3. Here we show that ME3 depletion selectively kills ME2-null PDAC cells in a manner consistent with an essential function for ME3 in these cancer cells. These
Genomic Deletion of Malic Enzyme 2 Confers Collateral Lethality in Pancreatic Cancer Read More »
In November, The University of Texas MD Anderson Cancer Center celebrated its 75th anniversary with a week-long series of events that raised nearly $15 million to support its efforts in patient care and in the investigation and treatment of cancer. Housed on 16 million square feet in the city of Houston, the cancer center has
MD Anderson Cancer Center Marks 75 Years of Research to End Cancer Read More »
Sign up for the latest news and updates from Ron DePinho, MD
